Biotech hasn’t been a great place to invest your money in 2018.The iShares Nasdaq Biotechnology Index, after all, is down by over 4% at present, and summer has historically been a down time for this high-risk space. So, there’s little reason to believe a widespread rally is coming anytime soon.
Even against this dour backdrop, however, several former top biotech stocks have turned out to be particularly disappointing investing vehicles this year. Acadia Pharmaceuticals (NASDAQ:ACAD) and Celgene Corporation (NASDAQ:CELG), for instance, are both trading near their 52-week lows right now. That’s a surprising turn of events given that Acadia and Celgene were two of the absolute best-performing growth stocks since about the start of 2010.
Image source: Getty Images.
Top Biotech Stocks To Buy For 2019: M&T Bank Corporation(MTB)
- [By Logan Wallace]
Get a free copy of the Zacks research report on M&T Bank (MTB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Coho Partners Ltd. raised its holdings in shares of M&T Bank (NYSE:MTB) by 24.1% in the 1st quarter, Holdings Channel reports. The firm owned 1,744 shares of the financial services provider’s stock after purchasing an additional 339 shares during the quarter. Coho Partners Ltd.’s holdings in M&T Bank were worth $322,000 at the end of the most recent quarter.
- [By Ethan Ryder]
M&T Bank (NYSE: MTB) and S.Y. Bancorp (NASDAQ:SYBT) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.
Top Biotech Stocks To Buy For 2019: ENGlobal Corporation(ENG)
- [By Max Byerly]
ENGlobal (NASDAQ:ENG) will be announcing its earnings results before the market opens on Wednesday, May 9th.
ENGlobal (NASDAQ:ENG) last released its quarterly earnings data on Thursday, March 15th. The construction company reported ($0.08) earnings per share for the quarter. ENGlobal had a negative net margin of 29.16% and a negative return on equity of 17.18%. The firm had revenue of $14.43 million during the quarter.
- [By Stephan Byrd]
Enigma (CURRENCY:ENG) traded 0.7% higher against the US dollar during the 24 hour period ending at 10:00 AM ET on June 17th. During the last seven days, Enigma has traded down 12% against the US dollar. Enigma has a market capitalization of $104.94 million and $2.86 million worth of Enigma was traded on exchanges in the last 24 hours. One Enigma token can now be bought for about $1.40 or 0.00021533 BTC on popular cryptocurrency exchanges including HitBTC, Vebitcoin, OKEx and GOPAX.
Top Biotech Stocks To Buy For 2019: Bank of Marin Bancorp(BMRC)
- [By Joseph Griffin]
Media headlines about Bank of Marin Bancorp (NASDAQ:BMRC) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bank of Marin Bancorp earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the bank an impact score of 46.5239093639876 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
- [By Max Byerly]
Shares of Bank of Marin Bancorp (NASDAQ:BMRC) have received a consensus rating of “Hold” from the six research firms that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $75.67.